Mats Dehlin1, Andreas E R Fasth2, Maximilian Reinhardt3, Lennart T H Jacobsson1. 1. Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 2. Medical Affairs, Novartis Sverige AB, Kista, Sweden. 3. Novartis Pharma AG, Basel, Switzerland.
Abstract
OBJECTIVES: Our aims were to determine if the Psoriasis Area Severity Index (PASI) score and serum urate (SU) levels were associated at baseline and whether the change in PASI score during 12 weeks of treatment resulted in a significant change in SU, adjusted for relevant confounders. METHODS: Data from patients with psoriasis/PsA (n = 1042/204) in three phase 3 randomized control trials treated with secukinumab (dose 300 mg, n = 628) or placebo (n = 414) were pooled. At baseline, values for SU, PASI and the following covariates were assessed: age, sex, BMI, estimated glomerular filtration rate, and medication with diuretics. To assess the changes in PASI (ΔPASI) and SU (Δurate), the differences (week 12 minus baseline) in patients receiving the active drug were used. Multivariable linear regression, adjusting for covariates, was used to assess the association between PASI and SU at baseline with all patients pooled and to assess the association between Δurate and ΔPASI over 12 weeks of treatment with secukinumab. RESULTS: The degree of skin involvement of psoriasis showed a statistically significant, albeit modest, association with SU (R 2 = 0.014, P < 0.0001 univariately), whereas known risk factors for hyperuricaemia had a much larger impact cross-sectionally at baseline (R 2 = 0.33, P < 0.0001). Furthermore, a substantial improvement in PASI score resulted in only a modest decrease of SU over 12 weeks of treatment with secukinumab (R 2 = 0.014, P < 0.0001 univariately). CONCLUSIONS: There is a statistically significant, albeit modest, association with both extent and change in PASI score and SU in patients with psoriasis, compatible with a potential pathophysiological relationship between urate and psoriasis. TRIAL REGISTRATION: ERASURE: clinicaltrials.gov, https://clinicaltrials.gov, NCT01365455; FIXTURE: clinicaltrials.gov, https://clinicaltrials.gov, NCT01358578; SCULPTURE: clinicaltrials.gov, https://clinicaltrials.gov, NCT01406938.
OBJECTIVES: Our aims were to determine if the Psoriasis Area Severity Index (PASI) score and serum urate (SU) levels were associated at baseline and whether the change in PASI score during 12 weeks of treatment resulted in a significant change in SU, adjusted for relevant confounders. METHODS: Data from patients with psoriasis/PsA (n = 1042/204) in three phase 3 randomized control trials treated with secukinumab (dose 300 mg, n = 628) or placebo (n = 414) were pooled. At baseline, values for SU, PASI and the following covariates were assessed: age, sex, BMI, estimated glomerular filtration rate, and medication with diuretics. To assess the changes in PASI (ΔPASI) and SU (Δurate), the differences (week 12 minus baseline) in patients receiving the active drug were used. Multivariable linear regression, adjusting for covariates, was used to assess the association between PASI and SU at baseline with all patients pooled and to assess the association between Δurate and ΔPASI over 12 weeks of treatment with secukinumab. RESULTS: The degree of skin involvement of psoriasis showed a statistically significant, albeit modest, association with SU (R 2 = 0.014, P < 0.0001 univariately), whereas known risk factors for hyperuricaemia had a much larger impact cross-sectionally at baseline (R 2 = 0.33, P < 0.0001). Furthermore, a substantial improvement in PASI score resulted in only a modest decrease of SU over 12 weeks of treatment with secukinumab (R 2 = 0.014, P < 0.0001 univariately). CONCLUSIONS: There is a statistically significant, albeit modest, association with both extent and change in PASI score and SU in patients with psoriasis, compatible with a potential pathophysiological relationship between urate and psoriasis. TRIAL REGISTRATION: ERASURE: clinicaltrials.gov, https://clinicaltrials.gov, NCT01365455; FIXTURE: clinicaltrials.gov, https://clinicaltrials.gov, NCT01358578; SCULPTURE: clinicaltrials.gov, https://clinicaltrials.gov, NCT01406938.
Authors: Richard G Langley; Boni E Elewski; Mark Lebwohl; Kristian Reich; Christopher E M Griffiths; Kim Papp; Lluís Puig; Hidemi Nakagawa; Lynda Spelman; Bárður Sigurgeirsson; Enrique Rivas; Tsen-Fang Tsai; Norman Wasel; Stephen Tyring; Thomas Salko; Isabelle Hampele; Marianne Notter; Alexander Karpov; Silvia Helou; Charis Papavassilis Journal: N Engl J Med Date: 2014-07-09 Impact factor: 91.245
Authors: Rosa Parisi; Deborah P M Symmons; Christopher E M Griffiths; Darren M Ashcroft Journal: J Invest Dermatol Date: 2012-09-27 Impact factor: 8.551